iBio, Inc. — Form 10-K
Filed August 28, 2026 · analyzed by the Periodic Agent
10-K
▲ Likely positive
significance 72/100
What the filing says
iBio, Inc. (market cap ~$22.4M) entered into an Assignment and Exclusive License Agreement with AstralBio, Inc. effective August 27, 2026. iBio acquired full ownership of AstralBio's Amylin Target intellectual property (antibodies, patents, know-how) and an exclusive worldwide license to develop, manufacture, and commercialize Program Products directed to the Amylin Target. iBio must pay AstralBio a $750,000 upfront fee (due within 30 days) and future milestone payments (amounts redacted; structure ties to equity or cash depending on listing status), plus a percentage of Program Product Licensing Proceeds. AstralBio retains a non-exclusive, royalty-free license to use assigned IP for non-Amylin-Target products.
Why this rating
Asset acquisition with upfront payment of $750K (~3.3% of market cap) plus milestone obligations; exclusive right to commercialize Amylin Target. Material for small biotech but contingent on development success.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.